S0819 Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab w/ or w/out Cetuximab in Patients with NSCLC

Investigator: Eric Bernicker, MD

Study Coordinator: Lacey Burey

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT00946712

Phone: 713.441.1159

IRB Number: Pro00008714

Description

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving carboplatin and paclitaxel are more effective with or without bevacizumab and/or cetuximab in treating patients with non-small cell lung cancer (NSCLC). PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or recurrent non-small cell lung cancer.
More to Explore